Good safety and improved erectile function reported from Dicot’s phase 1 study
Press release: Uppsala, April 23, 2024. Dicot's completed phase 1 clinical study demonstrates that the company's drug candidate LIB-01 has a very good safety profile, which was the primary objective of the study. In addition to this, the company can deduce an efficacy signal from the study where participants reported an improved erectile function, in some cases beyond 28 days post first dose.The primary objective of Dicot's phase 1 study has been to investigate the safety profile in humans for LIB-01, the company’s drug candidate for treatment of erectile dysfunction. In January, Dicot